The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Disclosure of Relevant Financial Relationships
Dr. Liu has the following financial relationships to disclose:
Consultant/Advisor/Speaker: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech/Roche, Gilead, GSK, Guardant Health, Johnson & Johnson, Jazz Pharmaceuticals, Lilly, Merck, Merus, Mirati, Natera, Novartis, OSE Immunotherapeutics, Pfizer, Regeneron, Revolution Medicines, Takeda, Yuhan
Researcher: Abbvie, Alkermes, AstraZeneca, Bristol-Myers Squibb, Cogent Biosciences, Duality, Elevation Oncology, Ellipses, Genentech, Gilead, Medilink, Merck, Nuvalent, OSE Immunotherapeutics, Puma, RAPT, Synthekine, SystImmuneDr. Sabari has the following financial relationships to disclose:
Research Support: (Institutional) Janssen, Loxo Lilly, Mirati/BMS, and Regeneron
Advisory Board/Consultant: AstraZeneca, AbbVie, EMD Serono, Genentech, Janssen, Jazz, Loxo Lilly, Mirati/BMS, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, and TakedaDr. Scott has the following financial relationships to disclose:
Research Support: Johnson & Johnson, Black Diamond Therapeutics, and Nuvalent
Consultant/Advisor/Speaker: AstraZeneca, Daiichi Sankyo, EMD Serono, Merus and Johnson & JohnsonHelena Yu, MD-planner
Dr. Yu has the following financial relationships to disclose:
Consultant/Advisor/Speaker: AstraZeneca, Daiichi, Janssen, Summit Therapeutics, BMS, Cullinan, Taiho, Amgen, AbbVie, and PfizerPartners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Target Audience
Academic and community-based oncologists, radiation oncologists, thoracic surgeons, advanced practice professionals (APPs), and other members of the multidisciplinary LC care team.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate efficacy and safety data with recently approved and emerging treatments for patients with SCLC to improve evidence-based decision-making among clinicians and related long-term outcomes for the individuals they manage
- Describe the roles of EGFR-targeted therapy and immunotherapy in the (neo)adjuvant treatment of stage III NSCLC to ensure clinicians are offering up-to-date therapeutic options to appropriate patients
- Create evidence-based treatment plans for patients with metastatic NSCLC harboring targetable driver mutations and/or overexpression of actionable biomarkers to ensure these individuals are receiving state-of-the-art care that best impacts their long-term survival
- Discuss emerging and investigational treatment options for patients with metastatic NSCLC to educate clinicians regarding newer treatment options as well as clinical trial opportunities
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Efficient LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
Partners designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Advanced Practice Professionals:
The American Association of Nurse Practitioners (NPs) accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME. Additionally, the American Academy of Physician Assistants (PAs) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from providers accredited by the ACCME. As a result, NPs and PAs will be included in the target audience for this activity and instructed to apply for credit from their individual governing bodies using the issued AMA credit.Disclaimer
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.Provider(s)/Educational Partner(s)
This activity is jointly provided by Efficient LLC and Partners for Advancing Clinical Education.
Commercial Support
This activity is supported by educational grants from AbbVie, AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Johnson & Johnson.
Additional Information
For additional information about the accreditation of this activity, please visit https://partnersed.com
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date: